drugset
drugset / Trial / NCT04990271

A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma

NCT04990271 ↗

Phase 2 Unknown 92 enrolled Chengdu Kanghong Biotech Co., Ltd. Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · collab
NaSingle-groupOpen-labelTreatment

Summary

This prospective, multi-center, open single-arm Phase II clinical trial is designed to investigate the efficacy and safety of intravenous chemotherapy combined with Conbercept intravitreal injection in the treatment of retinoblastoma.

Timeline

Start
2021-07-05
Primary completion
2023-04-15
Completion
2023-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Conbercept Protein / enzyme biologic — Intravitreal

Indications

retinoblastoma